Cabaletta Bio (CABA) EPS (Weighted Average and Diluted) (2021 - 2025)
Cabaletta Bio's quarterly EPS (Weighted Average and Diluted) came in at -$0.35 in Q4 2025, up 46.15% year-on-year from -$0.24 in Q4 2024, and up 20.45% quarter-over-quarter from -$0.44 in Q3 2025.
Cabaletta Bio has reported EPS (Weighted Average and Diluted) for 5 years, with the latest figure at -$0.35 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 46.15% year-over-year to -$0.35; the trailing twelve-month figure through Dec 2025 stood at -$2.23 (up 4.7% YoY), and the FY2025 full-year result was -$2.1, up 10.26% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$0.35, up from -$0.44 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.35 in Q4 2025, with the low at -$0.73 in Q2 2025.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.5, with a median of -$0.45 recorded in 2021.
- Year-over-year, EPS (Weighted Average and Diluted) slumped 67.57% in 2024 and surged 46.15% in 2025.
- Tracing CABA's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.49 in 2021, then dropped by 6.12% to -$0.52 in 2022, then grew by 9.62% to -$0.47 in 2023, then plunged by 38.3% to -$0.65 in 2024, then surged by 46.15% to -$0.35 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.35 (Q4 2025), -$0.44 (Q3 2025), and -$0.73 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | -0.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.35 |
| Sep 30, 2025 | -0.44 |
| Jun 30, 2025 | -0.73 |
| Mar 31, 2025 | -0.71 |
| Dec 31, 2024 | -0.65 |
| Sep 30, 2024 | -0.62 |
| Jun 30, 2024 | -0.56 |
| Mar 31, 2024 | -0.51 |
| Dec 31, 2023 | -0.47 |
| Sep 30, 2023 | -0.37 |
| Jun 30, 2023 | -0.37 |
| Mar 31, 2023 | -0.45 |
| Dec 31, 2022 | -0.52 |
| Sep 30, 2022 | -0.39 |
| Jun 30, 2022 | -0.45 |
| Mar 31, 2022 | -0.45 |
| Dec 31, 2021 | -0.49 |
| Sep 30, 2021 | -0.45 |
| Jun 30, 2021 | -0.45 |